News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma’s rights issue oversubscribed by 34 percent

December 17, 2014

PledPharma AB
Company Announcement

PledPharma’s rights issue oversubscribed by 34 percent

Stockholm, Not for distribution, directly or indirectly, in or into the United
States, Australia, Canada, Singapore, Switzerland, 2014-12-17 08:27 CET (GLOBE

The rights issue was subscribed to approximately 99,4 percent with subscription
rights (a total of 4 693 939 shares). In addition, 1 629 651 shares have been
applied for subscription without subscription rights, corresponding to
approximately 34,5 percent of the total offer. The rights issue was thus
oversubscribed by approximately 34 percent. Shares subscribed for without
subscription rights (a total of 30 541 shares), have been allocated to
shareholders in accordance with the principles set out in the prospectus.
Information regarding such allocation will only be sent to persons entitled to
allotment. PledPharma receives approximately SEK 75,6 million before issue

“It is invigorating to see the strong support of our existing shareholders and
the interest from new institutional investors. With this rights issue, we now
have the resources to run our new drug candidate Aladote™ against acetaminophen
induced acute liver failure through clinical phase II and up to a potential
partnering deal. Furthermore, this positions PledPharma financially well for
the upcoming partner negotiations regarding the drug candidate PledOx®, which
is in the final stage of the Phase IIb study PLIANT with the goal of reducing
some major serious and dose-limiting side effects from chemotherapy treatment
of colorectal cancer”, says CEO Jacques Näsström. 

The rights issue will increase the number of shares by 4 724 480 to a total of
28 346 883 shares and the share capital will increase by approximately SEK 248
657 to approximately SEK 1 491 941. 

After registration of the share capital increase at the Companies Registration
Office, the paid interim shares in the rights issue will be converted into new
shares. Trading in the new shares is expected to commence on Nasdaq First North
around the January 9, 2015. 

For further information please contact:

Jacques Näsström, CEO PledPharma, phone +46 73 713 09 79

Michaela Gertz, CFO PledPharma, phone +46 70 926 17 75

About PledPharma
PledPharma is a Swedish pharmaceutical company developing novel therapies for
life-threatening diseases. The company's initial goal is to develop a drug,
PledOx®, which reduces the serious side effects associated with chemotherapy.
In the latest project PP-100, Aladote™ and its ability to reduce or prevent the
development of acute liver failure due to paracetamol poisoning is evaluated.
Project PP-099 is based on limiting the damage that occurs to the heart muscle
when a patient suffers from acute myocardial infarction. The company has the
potential to offer patients valuable and unique treatments for severe,
life-threatening diseases for which there may be an opportunity for faster
registration process of the drug in the United States called "Breakthrough
therapy". The value of the current market for preventing and reducing serious
side effects from chemotherapy amounts according to Datamonitor to
approximately SEK 70 billion. PledPharma (STO: PLED) is listed on the Nasdaq
First North. Erik Penser AB is Certified Adviser. For more information, see 

Important notice

The information in this press release is not for release, publication or
distribution, directly or indirectly, in or into the United States, Australia,
New Zeeland, Hong Kong, Japan, Canada, Singapore, Switzerland or South Africa.
The distribution of this press release in certain other jurisdictions may be
restricted. The information in this press release shall not constitute an offer
to sell or the solicitation of an offer to purchase any securities in
PledPharma in any jurisdiction. This press release does not constitute, or form
part of, an offer or solicitation to purchase or subscribe for securities in
the United States. The securities referred to herein may not be offered or sold
in the United States absent registration or an exemption from registration as
provided in the U.S. Securities Act of 1933, as amended. PledPharma does not
intend to register any portion of the offering of the securities in the United
States or to conduct a public offering of the securities in the United States.
Copies of this announcement are not being distributed or sent and may not be
distributed or sent to the United States, Australia, New Zeeland, Hong Kong,
Japan, Canada, Singapore, Switzerland or South Africa. 

This document has not been approved by any regulatory authority. This document
is a press release and not a prospectus and investors should not subscribe for,
or purchase any securities referred to in this document, except on the basis of
information in the prospectus (including supplements thereto) which has been
published by PledPharma and is available, inter alia, on its web site. 

European Economic Area

PledPharma has not resolved to offer to the public shares or rights in any
Member State of the European Economic Area other than Sweden and any other
jurisdiction into which the offering of shares or rights may be passported.
Within such Member States of the European Economic Area other than Sweden (and
any other jurisdiction into which the offering of shares or rights may be
passported) and which has implemented the Prospectus Directive (each, a
"Relevant Member State"), no action has been undertaken as of this date to make
an offer to the public of shares or rights requiring a publication of a
prospectus in any Relevant Member State. As a result hereof, the shares or
rights may only be offered in Relevant Member States: (a) to a qualified
investor (as defined in the Prospectus Directive or under applicable law); or
(b) in any other respect that does not require that PledPharma publishes a
prospectus in accordance with Article 3(2) of the Prospectus Directive. 

For the purposes hereof, the expression an "offer to the public of shares or
rights" in any Relevant Member State means the communication, in any form, of
sufficient information on the terms of the offer and the shares or rights to be
offered so as to enable an investor to decide to purchase any securities, as
the same may be varied in a Relevant Member State due to the implementation of
the Prospectus Directive in that Member State and the expression "Prospectus
Directive" means Directive 2003/71/EC including any relevant implementing
measure in each Relevant Member State. 

Pareto Securities AB is acting for PledPharma and no one else in connection
with the rights issue and will not be responsible to anyone other than
PledPharma for providing the protections afforded to its clients or for
providing advice in relation to the rights issue and/or any other matter
referred to in this announcement. 

Pareto Securities AB accepts no responsibility whatsoever and makes no
representation or warranty, express or implied, for the contents of this
announcement, including its accuracy, completeness or verification or for any
other statement made or purported to be made by Pareto Securities AB, or on its
behalf, in connection with PledPharma and the new shares, the rights issue, and
nothing in this announcement is, or shall be relied upon as, a promise or
representation in this respect, whether as to the past or future. Pareto
Securities AB accordingly disclaims to the fullest extent permitted by law all
responsibility and liability whether relating to damages, contract or otherwise
which it might otherwise have in respect of this announcement or any such

Forward-looking statements

This press release may contain forward-looking statements that reflect the
company's current views with respect to future events and potential financial
performance. Although PledPharma believes that the expectations reflected in
such statements are reasonable, no assurance can be given that such
expectations will prove to have been correct. Accordingly, results can differ
materially from those set out in the forward-looking statements as a result of
various factors. You are advised to read this announcement, and the prospectus
and the information incorporated by reference therein, in their entirety for a
further discussion of the factors that could affect the PledPharma's future
performance and the industries in which PledPharma operates. In light of these
risks, uncertainties and assumptions, it is possible that the events described
in the forward-looking statements in this announcement may not occur.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10